![Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer](https://media.springernature.com/w200/springer-static/cover/journal/10120.jpg)
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer
![Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/0863f30f-8efe-4ba0-a570-7053cec36c69/gr1.gif)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12094-016-1528-7/MediaObjects/12094_2016_1528_Fig2_HTML.gif)
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase
![Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/3/1437/F1.large.jpg)
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
![LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment](https://www.lonsurfhcp.com/Content/img/mGEJ/lonsurf-metastatic-gej-cancer-reduced-progression-risk.png)
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
![Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/9/4605/F1.medium.gif)
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
![Frontiers | Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis Frontiers | Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis](https://www.frontiersin.org/files/Articles/734323/fonc-11-734323-HTML/image_m/fonc-11-734323-g005.jpg)
Frontiers | Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis
OncLive - The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
![Progress and challenges in HER2-positive gastroesophageal adenocarcinoma | Journal of Hematology & Oncology | Full Text Progress and challenges in HER2-positive gastroesophageal adenocarcinoma | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13045-019-0737-2/MediaObjects/13045_2019_737_Fig1_HTML.png)
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma | Journal of Hematology & Oncology | Full Text
![Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/3/1437/F2.large.jpg)
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
![Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm | Nature Reviews Clinical Oncology Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm | Nature Reviews Clinical Oncology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41571-021-00492-2/MediaObjects/41571_2021_492_Fig1_HTML.png)
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm | Nature Reviews Clinical Oncology
![LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment](https://www.lonsurfhcp.com/Content/img/mGEJ/lonsurf-metastatic-gej-cancer-reduced-progression-risk-mobile.png)
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
![Relative tumor volume (RTV) (a) and body weight change (BWC) (b) in... | Download Scientific Diagram Relative tumor volume (RTV) (a) and body weight change (BWC) (b) in... | Download Scientific Diagram](https://www.researchgate.net/publication/281206023/figure/fig3/AS:391514644598795@1470355773908/Relative-tumor-volume-RTV-a-and-body-weight-change-BWC-b-in-SC-2-gastric.png)
Relative tumor volume (RTV) (a) and body weight change (BWC) (b) in... | Download Scientific Diagram
![Scenario 1. FLOT, TAS-102, IOs Do They Improve the Lives of Patients With Gastric Cancer? - ppt download Scenario 1. FLOT, TAS-102, IOs Do They Improve the Lives of Patients With Gastric Cancer? - ppt download](https://slideplayer.com/17833282/106/images/slide_1.jpg)
Scenario 1. FLOT, TAS-102, IOs Do They Improve the Lives of Patients With Gastric Cancer? - ppt download
![Evolving Immuno-Chemotherapeutic Paradigms in Esophageal and Gastric Cancers | Published in healthbook TIMES Oncology Hematology Evolving Immuno-Chemotherapeutic Paradigms in Esophageal and Gastric Cancers | Published in healthbook TIMES Oncology Hematology](https://s3.amazonaws.com/production.scholastica/public/attachments/a58eb50a-ea22-41f3-871e-1a99b9b073ef/large/image1.png)
Evolving Immuno-Chemotherapeutic Paradigms in Esophageal and Gastric Cancers | Published in healthbook TIMES Oncology Hematology
![Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/d29b77e0-0e70-4130-8d61-55c8049ee38a/gr2.jpg)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Cancers | Free Full-Text | Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer Cancers | Free Full-Text | Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer](https://www.mdpi.com/cancers/cancers-14-05615/article_deploy/html/images/cancers-14-05615-g001.png)
Cancers | Free Full-Text | Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
![LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment](https://www.lonsurfhcp.com/Content/img/mGEJ/lonsurf-metastatic-gej-cancer-reduced-ecog-deterioration-risk.png)
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
![TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download](https://slideplayer.com/slide/14899254/91/images/7/Primary+Endpoint+%E2%80%93+OS+OS+%28%25%29+FTD%2FTPI+Placebo+Time+%28months%29.jpg)
TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
![Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/9/4605/F1.large.jpg)
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
![LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment](https://www.lonsurfhcp.com/Content/img/mGEJ/lonsurf-metastatic-gej-cancer-reduced-mortality-risk-mobile.png)
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
![Ramucirumab beyond progression plus TAS‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy - Goetze - 2023 - International Journal of Cancer - Wiley Online Library Ramucirumab beyond progression plus TAS‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy - Goetze - 2023 - International Journal of Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/b258c562-64fd-4dc2-91a4-7b998d3eeb57/ijc34652-toc-0001-m.png)